SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Abete I, Parra D, Crujeiras AB, Goyenechea E, Martinez JA. 2008. Specific insulin sensitivity and leptin responses to a nutritional treatment of obesity via a combination of energy restriction and fatty fish intake. J Hum Nutr Diet 21:591600.
  • Al-Massadi O, Crujeiras AB, Gonzalez RC, Pardo M, Dieguez C, Casanueva FF, Seoane LM. 2010. Age, sex, and lactating status regulate ghrelin secretion and GOAT mRNA levels from isolated rat stomach. Am J Physiol Endocrinol Metab 299:E341E350.
  • Blundell JE, Hebebrand J, Oppert JM. 2010. What is the value of obesity research? Obes Facts 3:279282.
  • Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. 2012. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463468.
  • Bray GA, Bellanger T. 2006. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29:109117.
  • Casanueva FF, Moreno B, Rodriguez-Azeredo R, Massien C, Conthe P, Formiguera X, Barrios V, Balkau B. 2009. Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin Endocrinol (Oxf) 73:3540.
  • Castillo-Quan J. 2012. From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech 5:293295.
  • Catalan V, Gomez-Ambrosi J, Rodriguez A, Salvador J, Fruhbeck G. 2009. Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother 10:239254.
  • Chaput JP, Tremblay A. 2006. Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol 62:793803.
  • Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG. 2013. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96101.
  • Cox B, Kislinger T, Emili A. 2005. Integrating gene and protein expression data: pattern analysis and profile mining. Methods 35:303314.
  • Crujeiras AB, Cueva J, Vieito M, Curiel T, Lopez-Lopez R, Pollan M, Casanueva FF. 2012. Association of breast cancer and obesity in a homogeneous population from Spain. J Endocrinol Invest 35:681685.
  • Crujeiras AB, Goyenechea E, Abete I, Lage M, Carreira MC, Martinez JA, Casanueva FF. 2010. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 95:50375044.
  • Crujeiras AB, Parra D, Goyenechea E, Abete I, Martinez JA. 2009. Tachyphylaxis effects on postprandial oxidative stress and mitochondrial-related gene expression in overweight subjects after a period of energy restriction. Eur J Nutr 48:341347.
  • Cunha A. 2012. Basic research: Irisin-behind the benefits of exercise. Nat Rev Endocrinol 8:195.
  • Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235241.
  • Foresta C, Strapazzon G, De Toni L, Gianesello L, Calcagno A, Pilon C, Plebani M, Vettor R. 2010. Evidence for osteocalcin production by adipose tissue and its role in human metabolism. J Clin Endocrinol Metab 95:35023506.
  • Friedman JM. 2002. The function of leptin in nutrition, weight, and physiology. Nutr Rev 60:S1S14; discussion S68-S84, 85–87.
  • Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. 2009. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94:18531878.
  • Goyenechea E, Parra D, Crujeiras AB, Abete I, Martinez JA. 2009. A nutrigenomic inflammation-related PBMC-based approach to predict the weight-loss regain in obese subjects. Ann Nutr Metab 54:4351.
  • Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR, Rodriguez-Artalejo F. 2011. Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: the ENRICA study. Obes Rev 13:388392.
  • Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. 2012. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:17251738.
  • Kelly DP. 2012. Medicine. Irisin, light my fire. Science 336:4243.
  • Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656660.
  • Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC. 2013. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 27:365369.
  • Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, Martinez JA, Zulet MA. 2013. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: the RESMENA randomized controlled trial. Nutr Metab (Lond) 10:22.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412419.
  • Mera R, Thompson H, Prasad C. 1998. How to calculate sample size for an experiment: a case-based description. Nutr Neursci 1:8791.
  • Montez JM, Soukas A, Asilmaz E, Fayzikhodjaeva G, Fantuzzi G, Friedman JM. 2005. Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal. Proc Natl Acad Sci USA 102:25372542.
  • Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Manuel-Fernandez-Real J. 2013. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769E778.
  • Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas M, Geladari EV, Young Huh J, Dincer F, Davis CR, Crowell JA, Mantzoros CS. Circulating Irisin in Relation to Insulin Resistance and the Metabolic Syndrome. J Clin Endocrinol Metab (in press).
  • Pedersen BK, Febbraio MA. 2012. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457465.
  • Pi-Sunyer X. 2009. The medical risks of obesity. Postgrad Med 121:2133.
  • Polonsky KS. 2000. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord 24(Suppl 2):S29S31.
  • Polyzos SA, Kountouras J, Shields K, Mantzoros CS. 2013. Irisin: a renaissance in metabolism? Metabolism 62:10371044.
  • Roberts MD, Bayless DS, Company JM, Jenkins NT, Padilla J, Childs TE, Martin JS, Dalbo VJ, Booth FW, Rector RS, et al. 2013. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 62:10521056.
  • Roca-Rivada A, Al-Massadi O, Castelao C, Senin LL, Alonso J, Seoane LM, Garcia-Caballero T, Casanueva FF, Pardo M. 2012. Muscle tissue as an endocrine organ: comparative secretome profiling of slow-oxidative and fast-glycolytic rat muscle explants and its variation with exercise. J Proteomics 75:54145425.
  • Roca-Rivada A, Alonso J, Al-Massadi O, Castelao C, Peinado JR, Seoane LM, Casanueva FF, Pardo M. 2011. Secretome analysis of rat adipose tissues shows location-specific roles for each depot type. J Proteomics 74:10681079.
  • Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belen Crujeiras A, Seoane LM, Casanueva FF, Pardo M. 2013. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 8:e60563.
  • Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. 2012. Irisin: a new potential hormonal target for treatment of obesity and type II diabetes. J Diabetes 4:196.
  • Seidell JC. 2000. Obesity, insulin resistance and diabetes–a worldwide epidemic. Br J Nutr 83(Suppl 1):S5S8.
  • Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. 2012. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index. Peptides 39:125130.
  • Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE. 2004. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 3:960969.
  • Timmons JA, Baar K, Davidsen PK, Atherton PJ. 2012. Is irisin a human exercise gene? Nature 488:E9E10; discussion E10-E11.
  • Villarroya F. 2012. Irisin, turning up the heat. Cell Metab 15:277278.
  • Wen MS, Wang CY, Lin SL, Hung KC. 2013. Decrease in irisin in patients with chronic kidney disease. PLoS One 8:e64025.
  • World Health Organization (WHO). 2009. Global health risks: mortality and burden of disease attributable to selected mayor risks. Geneva: WHO.
  • Wynne K, Stanley S, Bloom S. 2004. The gut and regulation of body weight. J Clin Endocrinol Metab 89:25762582.
  • Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, Han CK, Zhuang XJ, Lu Y, Li XJ, Yang SY, Li XY. 2013. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 59:557562.
  • Zulet MA, Bondia-Pons I, Abete I, de la Iglesia R, Lopez-Legarrea P, Forga L, Navas-Carretero S, Martinez JA. 2011. The reduction of the metabolic syndrome in Navarra-Spain (RESMENA-S) study: a multidisciplinary strategy based on chrononutrition and nutritional education, together with dietetic and psychological control. Nutr Hosp 26:1626.